Stock Analysis

European Growth Companies With High Insider Ownership To Watch

OM:MCOV B
Source: Shutterstock

As the European markets navigate a landscape of mixed stock index performances and ongoing trade discussions with the U.S., investors are keenly observing economic indicators such as inflation and industrial output. In this environment, growth companies with substantial insider ownership can be particularly appealing, as they often signal strong internal confidence and alignment of interests between management and shareholders.

Advertisement

Top 10 Growth Companies With High Insider Ownership In Europe

NameInsider OwnershipEarnings Growth
Xbrane Biopharma (OM:XBRANE)21.8%56.8%
Pharma Mar (BME:PHM)11.8%43.3%
MedinCell (ENXTPA:MEDCL)13.9%130.8%
Marinomed Biotech (WBAG:MARI)29.7%20.2%
KebNi (OM:KEBNI B)38.3%94.5%
Elliptic Laboratories (OB:ELABS)24.4%79%
CTT Systems (OM:CTT)17.5%37.9%
Circus (XTRA:CA1)24.7%94.8%
Bonesupport Holding (OM:BONEX)10.4%62.3%
Bergen Carbon Solutions (OB:BCS)12%63.2%

Click here to see the full list of 214 stocks from our Fast Growing European Companies With High Insider Ownership screener.

Here's a peek at a few of the choices from the screener.

PostNL (ENXTAM:PNL)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: PostNL N.V. offers postal and logistics services to businesses and consumers in the Netherlands, Europe, and internationally, with a market cap of €536.66 million.

Operations: The company's revenue is primarily derived from its Parcels segment, generating €2.39 billion, and the Mail in The Netherlands segment, contributing €1.33 billion.

Insider Ownership: 35.1%

Earnings Growth Forecast: 32.9% p.a.

PostNL is experiencing significant earnings growth, forecasted at 32.88% annually, outpacing the Dutch market's 9.1%. Despite a recent net loss of €17 million for Q1 2025, this marks an improvement from the previous year's €20 million loss. However, revenue growth remains modest at 1.9% per year and below the market average of 7.3%. The company faces challenges with high debt levels and volatile share prices but trades significantly below its estimated fair value.

ENXTAM:PNL Earnings and Revenue Growth as at Jul 2025
ENXTAM:PNL Earnings and Revenue Growth as at Jul 2025

Medicover (OM:MCOV B)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Medicover AB (publ) offers healthcare and diagnostic services in Poland, Sweden, and internationally, with a market cap of SEK43.03 billion.

Operations: The company's revenue segments include healthcare services at €1.17 billion and diagnostic services at €0.80 billion.

Insider Ownership: 11.2%

Earnings Growth Forecast: 23.5% p.a.

Medicover shows strong growth potential, with earnings forecasted to grow significantly at 23.5% annually, surpassing the Swedish market's average. Recent earnings reports highlight a substantial increase in net income and revenue for the first half of 2025. Despite no substantial insider buying recently, insider transactions have been more purchases than sales. Medicover’s innovative MRD assay development marks a promising advancement in personalized cancer treatment, potentially enhancing its market position and supporting future growth prospects.

OM:MCOV B Ownership Breakdown as at Jul 2025
OM:MCOV B Ownership Breakdown as at Jul 2025

Yubico (OM:YUBICO)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Yubico AB offers authentication solutions for computers, networks, and online services with a market cap of SEK12 billion.

Operations: The company's revenue primarily comes from its Security Software & Services segment, totaling SEK2.45 billion.

Insider Ownership: 36.5%

Earnings Growth Forecast: 23.9% p.a.

Yubico demonstrates strong growth potential with earnings expected to grow significantly at 23.9% annually, outpacing the Swedish market. Recent expansions, including YubiKey as a Service in the EU and increased delivery coverage, enhance its market reach and operational efficiency against phishing threats. Despite a decline in net income for Q1 2025, insider buying has been substantial recently, indicating confidence in future prospects. The company trades at good value compared to peers within the industry.

OM:YUBICO Earnings and Revenue Growth as at Jul 2025
OM:YUBICO Earnings and Revenue Growth as at Jul 2025

Where To Now?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com